StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
8189.HK$0.14-3.97%
Fair $0.14+0.0%

8189.HK

Tianjin TEDA Biomedical Engineering Company Limited

Basic Materials / Agricultural InputsHKSE

$0.14

-0.01 (-3.97%)

Fairly Valued+0.0%Fair Value $0.14Fund rank 24/100 · Data gapFallback financials|
SA 5/F
F-Score: 3/9
High DebtLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 15%

FCF escenarios

weak_data · normalized FCF $-28.8M · quality 42.3/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 42/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

5/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. Debt-to-Equity ratio is 8.98, above the 2.0 threshold ROE is -7.4%, below the 5% threshold
Thesis & Journal · 8189.HKLocal privado en este navegador · Tianjin TEDA Biomedical Engineering Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$309M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-743.0%

↓

Gross Margin

6.8%

↓

Debt/Equity

8.98

↑
52-Week Range$0
$0$1

TradingView lightweight chart

8189.HK price, volumen y niveles de valoración

Último $0.145Periodo -75.4%
Fair value: $0.145

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+9.0%

FCF CAGR

—

FCF margin

-12.0%

FCF / Net income

0.69x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $523.0M · net income $-90.8M · FCF $-62.8M

2022-FY → 2025-FY

Gross margin

6.8%+3.2% pts

Operating margin

1.2%+6.0% pts

Net margin

-17.4%-10.6% pts

FCF margin

-12.0%-6.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$523.0M$523.0M$385.5M$398.0M$403.7M
Net Income$-90.8M$-90.8M$-27.8M$-20.2M$-27.5M
EBITDA$-99.7M$-99.7M$-24.5M$4.8M$-2.3M
EPS-0.04-0.04-0.01-0.01-0.01
Gross Margin6.8%6.8%5.2%5.4%3.7%
Operating Margin1.2%1.2%-3.9%-2.5%-4.8%
Net Margin-17.4%-17.4%-7.2%-5.1%-6.8%
Balance Sheet
Debt/Equity8.988.987.221.541.46
Current Ratio0.750.75———
Cash Flow
Free Cash Flow$-62.8M$-62.8M$-28.8M$-15.6M$-21.6M
Returns
ROE-743.0%-743.0%-125.5%-40.4%-39.2%
Valuation
EV/EBITDA———53.54—
P/B24.6724.6724.383.725.40
Growth & Yield
Revenue Growth35.7%35.7%-3.1%-1.4%—
EPS Growth-199.3%-199.3%-37.7%26.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -62.8%

Total return

-62.8%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.01 → -0.04

Residual

-62.8%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-62.8%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.